Summary of medicine characteristics - DILUENT FOR HUMATROPE SOLVENT FOR SOLUTION FOR INJECTION
1 NAME OF THE MEDICINAL PRODUCT
Diluent for Humatrope, solvent for solution for injection. (6mg cartridges)
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Humatrope cartridges are supplied in a combination package with an accompanying syringe containing 3.15mL of solvent solution.
For excipients, see 6.1.
3 PHARMACEUTICAL FORM
Solvent for solution for injection.
The solvent is a clear solution.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
None stated.
4.2 Posology and method of administration
Route of administration: Humatrope is administered by subcutaneous injection after reconstitution.
4.3 Contraindications
Humatrope should not be reconstituted with the supplied solvent for patients with a known sensitivity to either metacresol or glycerol.
4.4 Special warnings and precautions for use
None stated.
4.5 Interaction with other medicinal products and other forms of interaction
None stated.
4.6 Fertility, Pregnancy and lactation
None stated.
4.7 Effects on ability to drive and use machines
4.7 Effects on ability to drive and use machinesNone stated.
4.8 Undesirable effects
None stated.
4.9 Overdose
None stated.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
None stated.
5.2 Pharmacokinetic properties
None stated.
5.3 Preclinical safety data
None stated
6 PHARMACEUTICAL PARTICULARS
6 PHARMACEUTICAL PARTICULARS6.1 List of excipients
Solvent syringes: glycerol, metacresol, water for injections, hydrochloric acid and sodium hydroxide
6.2 Incompatibilities
None stated.
6.3 Shelf life
Before reconstitution: 3 years.
After reconstitution: The product may be stored for a maximum of 28 days at 2°C to 8°C.
Daily room temperature exposure should not exceed 30 minutes.
6.4 Special precautions for storage
Store at 2°C to 8°C (in a refrigerator). Do not freeze.
6.5 Nature and contents of container
Humatrope is available in the following pack sizes:
Humatrope 6 mg: 1 cartridge (glass type I) with 6 mg of powder for solution for
injection, and 3.17 ml of solvent solution in a pre-filled syringe (glass type I) with a plunger (rubber). Pack size of 1, 5 and 10.
Not all pack sizes may be marketed.
6.6
Reconstitution: Each cartridge of Humatrope should be reconstituted using the accompanying solvent syringe and the solvent connector. To reconstitute, attach the solvent connector to the cartridge and then inject the entire contents of the pre-filled solvent syringe into the cartridge. The solvent connector automatically aims the stream of liquid against the glass wall of the cartridge. Following reconstitution, the cartridge should be gently rocked back and forth until the contents are completely dissolved. DO NOT SHAKE. The resulting solution should be clear, without particulate matter. If the solution is cloudy or contains particulate matter, the contents MUST NOT be injected.
Humatrope cartridges can be used in conjunction with compatible CE marked pen injection systems. The manufacturer’s instructions with each individual pen must be followed for loading the cartridge, attaching the needle and administering the Humatrope injection.
The solvent connector is for single use only. Discard it after use. A sterile needle should be used for each administration of Humatrope.
7 MARKETING AUTHORISATION HOLDER
Eli Lilly Nederland B.V.
Papendorpseweg 83
3528 BJ Utrecht
The Netherlands
8 MARKETING AUTHORISATION NUMBER(S)
PL 14895/0293